NASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis $17.16 +0.15 (+0.88%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$17.16 0.00 (-0.03%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Dyne Therapeutics Stock (NASDAQ:DYN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dyne Therapeutics alerts:Sign Up Key Stats Today's Range$16.42▼$17.3450-Day Range$14.25▼$24.2852-Week Range$14.00▼$27.31Volume1.67 million shsAverage Volume2.54 million shsMarket Capitalization$3.21 billionP/E RatioN/ADividend YieldN/APrice Target$31.29Consensus RatingModerate Buy Company Overview Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company’s programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product. Founded in 2017 and based in Waltham, Massachusetts, Dyne is led by President and Chief Executive Officer John Cox. Its research and clinical development activities are primarily based in the United States.AI Generated. May Contain Errors. Read More Dyne Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreDYN MarketRank™: 3.324809861 of 5 starsDyne Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 275th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingDyne Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 1 strong buy rating, 11 buy ratings, 2 hold ratings, and 2 sell ratings.Upside PotentialDyne Therapeutics has a consensus price target of $31.29, representing about 82.3% upside from its current price of $17.16.Amount of Analyst CoverageDyne Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dyne Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.81) to ($3.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.37% of the float of Dyne Therapeutics has been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 10.81, which indicates bearish sentiment.Change versus previous monthShort interest in Dyne Therapeutics has recently decreased by 4.28%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.24 News SentimentDyne Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Dyne Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows2 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold 519.44% more of their company's stock than they have bought. Specifically, they have bought $40,000.00 in company stock and sold $247,777.00 in company stock.Percentage Held by Insiders9.46% of the stock of Dyne Therapeutics is held by insiders.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dyne Therapeutics' insider trading history. Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DYN Stock News HeadlinesHC Wainwright Expects Weaker Earnings for Dyne TherapeuticsNovember 12 at 1:43 AM | americanbankingnews.comDyne Therapeutics to Participate in Upcoming Investor ConferenceNovember 11, 2026 | globenewswire.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 15 at 1:00 AM | Behind the Markets (Ad)Brokers Set Expectations for DYN Q2 EarningsNovember 9, 2026 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Stock Price Breaks Above Fifty Day Moving Average Following Weak EarningsNovember 8, 2026 | americanbankingnews.comIs Dyne Therapeutics (DYN) Undervalued After Wider Losses And FDA Priority Review?November 5, 2026 | finance.yahoo.comDyne Therapeutics Reports Q3 2026 Results; Advances DMD And DM1 Programs Ahead Of 2027 MilestonesNovember 5, 2026 | rttnews.comDyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028November 5, 2026 | rttnews.comSee More Headlines DYN Stock Analysis - Frequently Asked Questions How have DYN shares performed this year? Dyne Therapeutics' stock was trading at $19.56 at the beginning of 2026. Since then, DYN shares have decreased by 12.3% and is now trading at $17.16. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.91) by $0.15. When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $208 million in an initial public offering on Thursday, September 17th 2020. The company issued 12,251,578 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' top institutional investors include State Street Corp (4.36%), Aberdeen Group plc (0.72%), Marshall Wace LLP (0.37%) and Jump Financial LLC (0.18%). Insiders that own company stock include Venture Fund Xi LP Atlas, Jason P Rhodes, John Cox, Oxana Beskrovnaya, Douglas Kerr, Johanna Friedl-Naderer, Wildon Farwell, Susanna Gatti High, Richard William Scalzo, Erick Lucera, Dirk Kersten, Brian S Posner and Carlo Incerti. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dyne Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Definium Therapeutics (DFTX) and Alphabet (GOOG). Company Calendar Last Earnings11/05/2026Today11/15/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 3 days ago, DYN's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees258Year Founded2018Price Target and Rating Average Price Target for Dyne Therapeutics$31.29 High Price Target$50.00 Low Price Target$10.00 Potential Upside/Downside+82.3%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($3.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$446.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-69.73% Return on Assets-53.82% Debt Debt-to-Equity Ratio0.21 Current Ratio12.99 Quick Ratio12.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.97 per share Price / Book3.45Miscellaneous Outstanding Shares187,330,000Free Float169,607,000Market Cap$3.21 billion OptionableOptionable Beta1.22 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:DYN) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
